An innovative immunotherapeutic strategy for ovarian cancer: CLEC10A and glycomimetic peptides

Table 3 Ratios of the levels of selected cytokines in sera from treated vs. untreated animals

Cytokine	Tumor-bearing	Expression	Healthy
IL-1α	2.7	Activated Macrophages	0.86
IL-12p70	3.5	Dendritic cells and macrophages	No change
IL-16	4	Released by lymphocytes	0.57
IL-27	4.5	Antigen-presenting cells, promotes Th1 responses	0.55
IL-28	4.3	Augments IFN-γ release, cytotoxic potential of CD8⁺ T cells	High*
IL-31	3.5	Activated Th2 T cells	High*
MIP-2/CXCL2	~ 6	Secreted by monocytes and macrophages	No change
Pentraxin3	~ 4	Mononuclear phagocytes, dendritic cells and neutrophils	0.21
SPARC	~ 5	Osteoblasts, macrophages at site of wound repair	No change
TIMP-2	3	Metastasis suppressor, expressed by monocytes, placenta	0.45
TNFα	45*	Activated monocytes and macrophages	0.21
TLR2	4.2	Activated monocytes, DCs, macrophages, B and T cells	0.37
Lymphotoxin-α	12.5*	Produced by Th1 T cells	0.74
sHVEM	~ 2	Activated monocytes and lymphocytes	10
IFN-γ	High^*	Activated lymphocytes	No change
CCL1	2.5	Activated T cells	No change
Lymphotactin	~ 3	Activated CD8⁺ cells	2.6

Markers of lymphocyte and monocyte activation in response to 0.1 nmole/g svL4 in Balb/c mice bearing breast tumors are compared with healthy mice. Sera from three animals were pooled for analysis with an array of 308 soluble factors. (*In these samples, the control value was negligible or low, thus the fold increase for treated samples appears high)